Point of Care Infectious Disease Testing Market By Product Type (Instruments, Reagents and Kits, Test Strips and Cards), By Technology (Immunoassays, Nucleic Acid Amplification, Chromatography-Based Tests, Biosensors), By Disease Type (HIV/AIDS, Hepatitis, COVID-19, Influenza, Malaria, Tuberculosis), By End-User (Hospitals, Clinics, Home Care, Diagnostic Laboratories), and By Region; Global Insights & Forecast (2023– 2030)

As per Intent Market Research, the Point of Care Infectious Disease Testing Market was valued at USD 10.9 billion in 2024-e and will surpass USD 14.9 billion by 2030; growing at a CAGR of 5.4% during 2025 - 2030.

The Point of Care (POC) infectious disease testing market has experienced significant growth, driven by the increasing demand for rapid diagnostics, especially in the context of infectious diseases like COVID-19, HIV, and influenza. The rise in the prevalence of infectious diseases, coupled with advancements in POC technologies, has propelled the adoption of POC testing solutions across healthcare settings. Moreover, the need for timely diagnosis, particularly in remote areas or home settings, is pushing the demand for more efficient and user-friendly testing solutions. The market is expected to continue its expansion, driven by innovations in testing technologies and increasing accessibility to healthcare.

Instruments Segment is Largest Owing to Advancements in Diagnostic Tools

Among the various product types in the Point of Care infectious disease testing market, Instruments hold the largest market share. The demand for advanced, compact, and accurate diagnostic instruments is particularly high in hospitals, diagnostic laboratories, and clinics. Instruments such as handheld analyzers, portable PCR machines, and immunoassay analyzers are increasingly being used for rapid diagnosis, especially in emergency and critical care situations. Their ability to deliver real-time, accurate results for a wide range of infectious diseases makes them indispensable in healthcare settings, particularly in resource-constrained environments.

Instruments' large share is attributed to their wide adoption across healthcare facilities and the continuous technological advancements that enhance their diagnostic capabilities. The integration of cloud-based analytics, improved sensitivity, and multi-disease testing options have further cemented the role of instruments in infectious disease testing. These innovations ensure faster results, greater accuracy, and improved patient outcomes, driving the continued growth of this segment.

Immunoassays Segment is Fastest Growing Owing to High Demand for Quick Diagnostics

The Immunoassays technology segment is the fastest-growing within the Point of Care infectious disease testing market. Immunoassays are widely used for detecting diseases such as HIV, malaria, influenza, and more due to their ability to provide rapid results with high sensitivity and specificity. These assays, which include lateral flow immunoassays (LFIs) and enzyme-linked immunosorbent assays (ELISAs), are particularly favored in POC settings for their ease of use and cost-effectiveness. Their ability to detect specific antibodies or antigens related to infectious pathogens makes them critical for quick diagnosis, especially in emergency or remote healthcare settings.

Immunoassays are particularly beneficial in environments where laboratory testing is not readily available, such as rural or low-resource areas. The growing demand for rapid testing, especially during outbreaks of infectious diseases like COVID-19, has significantly accelerated the adoption of immunoassay-based tests. As diagnostic needs continue to increase globally, this segment is poised for rapid expansion, driven by technological advancements and the need for faster, more reliable testing solutions.

HIV/AIDS Segment is Largest Owing to Global Prevalence and Awareness

The HIV/AIDS disease type segment is the largest in the Point of Care infectious disease testing market. HIV testing is a routine and critical aspect of managing the ongoing global epidemic, with millions of people worldwide requiring regular monitoring. The increasing global awareness of HIV/AIDS and the growing emphasis on early detection and treatment have significantly boosted the demand for rapid HIV tests. These tests help diagnose the infection early, enabling timely intervention and improving patient outcomes by reducing the spread of the virus.

POC HIV tests, such as rapid antibody tests and nucleic acid-based tests, are widely used in clinics, hospitals, and home settings, offering quick and reliable results. The extensive availability of these tests, coupled with the increasing adoption of testing programs in both developed and developing regions, is expected to continue driving the dominance of the HIV/AIDS segment in the market.

Hospitals Segment is Largest Owing to High Patient Volume and Demand

The Hospitals end-user segment is the largest in the Point of Care infectious disease testing market. Hospitals have the highest volume of patients requiring diagnostic testing, particularly for infectious diseases. The demand for rapid and accurate diagnostic results within hospitals is critical to managing patient care effectively. Point of Care testing in hospitals helps expedite patient treatment by providing immediate results, which is crucial for timely decision-making in emergency or critical care settings.

The increased focus on improving patient care, reducing diagnostic turnaround time, and enhancing operational efficiency in hospitals has driven the adoption of POC testing solutions. As hospitals continue to invest in advanced diagnostic technologies to provide better healthcare, the demand for POC infectious disease testing is expected to remain high within this segment.

North America Region is Largest Owing to Advanced Healthcare Infrastructure

North America holds the largest share of the Point of Care infectious disease testing market, owing to its advanced healthcare infrastructure, widespread adoption of innovative technologies, and high demand for rapid diagnostic solutions. The region's well-established healthcare system, along with an increasing focus on decentralized and home-based healthcare, has facilitated the growth of the POC testing market. The United States, in particular, is a major contributor, with a large number of hospitals, clinics, and diagnostic laboratories adopting POC testing solutions for infectious diseases.

The COVID-19 pandemic further accelerated the adoption of POC testing in North America, as the demand for quick and efficient diagnostics surged. With continuous advancements in POC technologies, such as improved immunoassays and nucleic acid amplification tests, the region is expected to maintain its leadership position in the market.

Leading Companies and Competitive Landscape

The Point of Care infectious disease testing market is highly competitive, with leading companies such as Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, and BD dominating the landscape. These companies are continuously innovating and expanding their product portfolios to meet the growing demand for rapid diagnostic solutions. Strategic partnerships, acquisitions, and new product launches are common in this market, as companies aim to strengthen their technological capabilities and expand their geographic reach.

For example, Abbott Laboratories has been a key player with its wide range of POC testing solutions, including the BinaxNOW COVID-19 test, while Roche Diagnostics focuses on offering molecular diagnostic tools for infectious disease testing. As the market continues to grow, the competition will intensify, with companies striving to capture market share by offering cutting-edge, cost-effective, and user-friendly diagnostic solutions.

Recent Developments:

• Abbott Laboratories launched a new rapid test for COVID-19 that delivers results in as little as 15 minutes, catering to the increasing demand for fast, at-home testing solutions.
• Thermo Fisher Scientific acquired the Point-of-Care testing business of Mesa Biotech, strengthening its position in the molecular diagnostics market, particularly for COVID-19.
• Siemens Healthineers received CE marking for its new compact POC platform that provides fast testing for a range of infectious diseases, focusing on influenza and respiratory infections.
• Cepheid announced a partnership with Hologic Inc. to jointly develop integrated solutions for the rapid testing of infectious diseases, expanding their reach in decentralized diagnostics.
• BD received FDA clearance for its new Point of Care system designed for the quick detection of HIV, enabling healthcare providers to offer faster diagnostics in clinical settings.

List of Leading Companies:

• Abbott Laboratories
• Roche Diagnostics
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Siemens Healthineers
• BD (Becton, Dickinson, and Company)
• Bio-Rad Laboratories
• Cepheid
• Quidel Corporation
• Hologic Inc.
• Alere Inc. (Now part of Abbott)
• MedMira Inc.
• Chembio Diagnostics, Inc.
• Mettler-Toledo International, Inc.
• Labcorp

Report Scope: